Topics

Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 Pipeline Review, H2 2018 [Report Updated: 26092018] Prices from USD $3500

20:16 EST 28 Nov 2018 | BioPortfolio Report Blog

Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 Pipeline Review, H2 2018


Summary


Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Coagulation Factor XI Pipeline Review, H2 2018, outlays comprehensive information on the Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Zdependent protease inhibitor. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 5, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Bleeding And Clotting Disorders, Arterial Thrombosis, Hemophilia C Factor XI Deficiency, Sepsis, Venous Thromboembolism, Acute Ischemic Stroke, Hemorrhagic Fever, Stroke and Venous Vein Thrombosis.


Furthermore, this report also reviews key players involved in Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27

The report reviews Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics and enlists all their major and minor projects

The report assesses Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 Pipeline Review, H2 2018 [Report Updated: 26092018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Coagulation Factor XI Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27 Pipeline Review, H2 2018 [Report Updated: 26092018] Prices from USD $3500"

Quick Search

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...